Pharmaceutical

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.

Jun 26, 2024 - 04:00
Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.
Read the original article

Tags:

Previous Article

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Next Article

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Hong Kong approves Leqembi for Alzheimer’s treatment

Hong Kong approves Leqembi for Alzheimer’s treatment

Jul 12, 2024

Zealand Pharma files patent for pharmaceutical composit...

Mar 13, 2024

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen submits sBLA to FDA for NSCLC combination therapy

Aug 28, 2023